Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy

23 Dec 2016

Abstract excerpt

Genome sequencing has uncovered an array of recurring somatic mutations in different non-Hodgkin lymphoma (NHL) subtypes. If affecting protein-coding regions, such mutations may yield mutation-derived peptides that may be presented by HLA class I proteins and recognized by cytotoxic T cells. A recurring somatic and oncogenic driver mutation of the Toll-like receptor adaptor protein MYD88, Leu265Pro (L265P) was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Immune Cell Function and Interaction
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28405493
DOI: 10.1080/2162402x.2016.1219825

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapyPMID 28405493Read ↗

Oncogenic MYD88 mutations in lymphoma: novel insights and therapeutic possibilities.Semantic proximity Read ↗

High-affinity T-cell receptor specific for MyD88 L265P mutation for adoptive T-cell therapy of B-cell malignancies.Semantic proximity Read ↗

MYD88 expression and L265P mutation in mature B-cell non-Hodgkin lymphomas.Semantic proximity Read ↗

MYD88 gene and protein: molecular architecture, signalling mechanisms and clinical implications in lymphoid malignancies.Semantic proximity Read ↗

Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphomaSemantic proximity Read ↗

Oncogenically active MYD88 mutations in human lymphoma.Semantic proximity Read ↗

Clinical significance of MYD88 non-L265P mutations in diffuse large B-cell lymphoma.Semantic proximity Read ↗

MYD88 in the driver's seat of B-cell lymphomagenesis: from molecular mechanisms to clinical implications.Semantic proximity Read ↗

The oncogenic human B-cell lymphoma MYD88 L265P mutation genocopies activation by phosphorylation at the Toll/interleukin-1 receptor (TIR) domainSemantic proximity Read ↗

Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.Semantic proximity Read ↗

[MyD88 L265P mutation and B cell tumor].Semantic proximity Read ↗

Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.